Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 27, 2022; 14(7): 1319-1332
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1319
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1319
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
Dario Spanu, Andrea Pretta, Eleonora Lai, Mara Persano, Clelia Donisi, Stefano Mariani, Marco Dubois, Marco Migliari, Giorgio Saba, Pina Ziranu, Valeria Pusceddu, Marco Puzzoni, Giorgio Astara, Mario Scartozzi, Medical Oncology Unit, University Hospital and University of Cagliari, Monserrato 09042, Cagliari, Italy
Author contributions: Spanu D, Pretta A, Lai E, Persano M, Donisi C, Mariani S, Dubois M, Migliari M, Saba G, Ziranu P, Pusceddu V, Puzzoni M, Astara G, Scartozzi M wrote and edited the manuscript; All authors meet conditions 1, 2 and 3.
Conflict-of-interest statement: Eleonora Lai has received advisory board and consultant fees from AstraZeneca and MSD. Mario Scartozzi has received consultant, advisory board and speakers’ bureau fees from Amgen, Sanofi, MSD, EISAI, Merck, Bayer.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mario Scartozzi, MD, Chairman, Full Professor, Medical Oncology Unit, University Hospital and University of Cagliari, SS 554 km 4500 Bivio per Sestu, Monserrato 09042, Cagliari, Italy. marioscartozzi@gmail.com
Received: January 31, 2022
Peer-review started: January 31, 2022
First decision: March 25, 2022
Revised: April 11, 2022
Accepted: July 11, 2022
Article in press: July 11, 2022
Published online: July 27, 2022
Processing time: 177 Days and 0.3 Hours
Peer-review started: January 31, 2022
First decision: March 25, 2022
Revised: April 11, 2022
Accepted: July 11, 2022
Article in press: July 11, 2022
Published online: July 27, 2022
Processing time: 177 Days and 0.3 Hours
Core Tip
Core Tip: The gut-liver axis plays an important role in the pathogenesis of liver diseases, including hepatocellular carcinoma (HCC). Growing evidence has supported the role of the gut microbiota in the development of HCC and as a prognostic and predictive factor. Thus, manipulation of the gut microbiota might represent a novel way to treat or prevent HCC.